Latest Lakefront Biotherapeutics News & Updates

See the latest news and media coverage for Lakefront Biotherapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Lakefront Biotherapeutics

Biotechnology acquisition and development firm

lakefrontbio.com

Headquarters: Mechelen, Belgium
Founded year: 1999
Company type: Public company
Number of employees: 50–200

Last updated Today

Latest news about Lakefront Biotherapeutics

In short: Lakefront Biotherapeutics rebranded from Galapagos, completed the acquisition of Ouro Medicines with Gilead, and launched a €50 million stock buyback.

Company announcements

June 8 Lakefront Biotherapeutics

Lakefront appoints Eric Hedrick MD as Chief Medical Officer

He will lead clinical development and join the Management Committee, supporting the company's transformation after the Ouro Medicines acquisition.

June 4 Lakefront Biotherapeutics

Lakefront Biotherapeutics and Gilead Sciences complete Ouro Medicines acquisition

The deal adds gamgertamig to Gilead's inflammation portfolio, with Lakefront leading early studies and receiving tiered royalties.

May 6 Lakefront Biotherapeutics

Galapagos becomes Lakefront Biotherapeutics on May 8

Ticker changes from GLPG to LKFT. New LinkedIn page serves as primary update channel. Old page remains live during transition.

May 6 Lakefront Biotherapeutics

Lakefront Biotherapeutics reports financial results for first quarter 2026

Net profit of €14.5 million, name change approved, and collaboration with Gilead for gamgertamig progresses.

Media coverage

June 12 Belegger.nl

Market Flash: Kepler Cheuvreux raises price target for Lakefront slightly

Kepler Cheuvreux raised the price target for Lakefront Biotherapeutics from 23.50 to 24.50 euros, but maintained the Reduce rating. This emerged Friday from an analyst report.

June 9 Yahoo Finance

Lakefront Announces Initiation of €50 Million Stock Repurchase Program

CET; regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the "Program"), under which the...

June 7 Yahoo Finance

Gilead Sciences (GILD), Lakefront Biotherapeutics Acquire Ouro Medicines to Advance Autoimmune Pipeline

Gilead Sciences Inc. (NASDAQ:GILD) is one of the best quality growth stocks to buy. On June 4, Gilead Sciences and Lakefront Biotherapeutics completed the acquisition...

June 4 Yahoo Finance

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE

Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases Foster City, Calif. and Mechelen, Belgium...

Never miss news about Lakefront Biotherapeutics

Track Lakefront Biotherapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.